hTERT-promoter-based tumor-specific expression of MCP-1 effectively sensitizes cervical cancer cells to a low dose of cisplatin

Cancer Gene Therapy

Volumn 11, Issue 1, 2004, Pages 1-7

  Nakamura, Mitsuhiro ^a   Kyo, Satoru ^a   Kanaya, Taro ^a   Yatabe, Noriyuki ^a   Maida, Yoshiko ^a   Tanaka, Masaaki ^a   Ishida, Yuko ^a   Fujii, Chifumi ^a   Kondo, Toshikazu ^a   Inoue, Masaki ^a   Mukaida, Naofumi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Cervical cancer; Cisplatin; hTERT promoter; MCP 1

Indexed keywords

CHEMOKINE; CISPLATIN; MONOCYTE CHEMOTACTIC PROTEIN 1; RETROVIRUS VECTOR; RNA DIRECTED DNA POLYMERASE; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CARCINOGENESIS; CELL CLONE; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIZATION; DRUG SPECIFICITY; ENZYME ACTIVITY; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENETICS; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MONOCYTE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; TUMOR GROWTH; UTERINE CERVIX CANCER;

ANIMALS; CELL DIVISION; CELL LINE, TUMOR; CHEMOKINE CCL2; CISPLATIN; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; MACROPHAGES; MICE; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS (GENETICS); TELOMERASE; UTERINE CERVICAL NEOPLASMS;

ANIMALIA; UNIDENTIFIED RETROVIRUS; VECTORS;

EID: 0347356413     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700650     Document Type: Article

References (32)

1. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer. N Eng J Med. 1999;340:1137-1143.
2. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Eng J Med. 1999;340:1144-1153.
3. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compare with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Eng J Med. 1999;340:1154-1161.
4. Zagozdzon R, Golab J. Immunomodulation by anticancer chemotherapy: more is not always better [Review]. Int J Oncol. 2001;18:417-424.
5. Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med. 1989;169:1485-1490.
6. Furutani Y, Nomura H, Notake M, et al. Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF). Biochem Biophy's Res Commun. 1989;159:249-255.
7. Rollins BJ, Sunday ME. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol Cell Biol. 1991;11:3125-3131.
8. Nokihara H, Yanagawa H, Nishioka Y, et al. Natural killer cell-dependent suppression of systemic spread of human lung adenocarcinoma cells by monocyte chemoattractant protein-1 gene transfection in severe combined immunodeficient mice. Cancer Res. 2000;60:7002-7007.
9. Greider CW, Blackburn EH. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomerase repeat synthesis. Nature. 1989;337:331-337.
10. Harley CB, Futcher BA, Greider CW. Telomerase shorten during ageing of human fibroblasts. Nature. 1990;345:458-460.
11. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.
12. Meyerson M, Counter CM, Eaton EN, et al. HEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997;90:785-795.
13. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997;277:955-959.
14. Takakura M, Kyo S, Kanaya T, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 1999;59:551-557.
15. Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet. 1999;8:137-142.
16. Horikawa I, Cable PL, Afshari C, et al. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res. 1999;59:826-830.
17. Kyo S, Takakura M, Taira T, et al. Sp 1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. 2000;28:669-677.
18. Kyo S, Inoue M. Complex regulatory mechanisms of telomerase activity in normal and cancer cells: how can we apply them for cancer therapy. Oncogene. 2002;21:688-697.
19. Gu J, Kagawa S, Takakura M. et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enable targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res. 2000;60:5359-5364.
20. Wada T, Furuichi K, Segawa-Takaeda C, et al. MIP-1 alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int. 1999;56:995-1003.
21. Ozawa K, Kondo T, Hori O, et al. Expression of the oxygen-regulated protein ORP150 accelerates wound healing by modulating intracellular VEGF transport. J Clin Invest. 2001;108:41-50.
22. Kondo Y, Komata T, Kondo S. Combination therapy of 2-5A antisense against telomerse RNA and cisplatin for malignant gliomas. Int J Oncol. 2001;18:1287-1292.
23. Bottazzi B, Walter S, Govoni D, et al. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J Immunol. 1992;148:1280-1285.
24. Singh RK, Berry K, Matsushima K, et al. Synergism between human monocyte chemotactic and activating factor and bacterial products for activation of tumoricidal properties in murine macrophages. J Immunol 1993;151:2786-2793.
25. Huang S, Singh RK, Xie K, et al. Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol Immnother. 1994;39:231-238.
26. Huang S, Xie K, Singh RK, et al. Suppression of tumor growth and metastasis of murine renal adenocarcinoma by syngeneic fibroblasts genetically engineered to secrete the JE/MCP-1 cytokine. J Interferon Cytoline Res. 1995;15:655-665.
27. Nishioka Y, Yano S, Fujiki F, et al. Combined therapy of multidrug-resistant human lung cancer with anti-P-glycoprotein antibody and monocyte chemoattractant protein-1 gene transduction: the possibility of immunological overcoming of multidrug resistance. Int J Cancer. 1997;71:170-177.
28. Nokihara H, Nishioka Y, Yano S, et al. Monocyte chemoattractant protein-1 gene modification of multidrug-resistant human lung cancer enhances antimetastatic effect of therapy with anti-P-glycoprotein antibody in SCID mice. Int J Cancer. 1999;80:773-780.
29. Sakai Y, Kaneko S, Nakamoto Y, et al. Enhanced antitumor effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein-1 in hepatocellular carcinoma. Cancer Gene Ther. 2001;8:695-704.
30. Garzetti GG, Ciavattini A, Provinciali M, et al. Expression of p53 and apoptosis of tumor cells in locally advanced cervical carcinoma after cisplatin based neoadjuvant chemotherapy. Anticancer Res. 1996;16:3229-3234.
31. Kaneko S, Hallenbeck P, Kotani T, et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 1995;55:5283-5287.
32. Yu D, Chen D, Chiu C, et al. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther. 2001:8:628-635.